Susan A. Gregory
Nessuna posizione attualmente
Profilo
Susan A.
Gregory was the founder and had founded Altair Therapeutics, Inc. in 2007, where she held the title of Chief Scientific Officer from 2007 to 2011.
She worked as a Principal at Pfizer Inc. from 1999 to 2000.
She also worked as a Vice President at Ionis Pharmaceuticals, Inc. and as an Assistant Professor at The University of Chicago.
Dr. Gregory received her undergraduate and doctorate degrees from the University of Illinois.
Precedenti posizioni note di Susan A. Gregory
| Società | Posizione | Fine |
|---|---|---|
Altair Therapeutics, Inc.
 Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Fondatore | 09/03/2011 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2000 |
| The University of Chicago | Corporate Officer/Principal | - |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Susan A. Gregory
| University of Illinois | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
- Borsa valori
- Insiders
- Susan A. Gregory
